Drug Discovery Approaches toward Anti-Parasitic Agents

Apicomplexan Parasites: Molecular Approaches toward Targeted Drug Development

Volumn , Issue , 2011, Pages 3-20

  Rohwer, Andreas ^a   Marhöfer, Richard J ^a   Caffrey, Conor R ^b   Selzer, Paul M ^a  

^a Intervet Innovation GmbH   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antiparasitic agents; Drug discovery; Lead discovery; Lead optimization; Profiling; Target identification; Target validation

Indexed keywords

EID: 79959799307     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527633883.ch1     Document Type: Chapter

References (79)

1. Renslo, A.R., and McKerrow, J.H. (2006) Drug discovery, and development for neglected parasitic diseases. Nat. Chem. Biol., 2, 701-710.
2. Don, R. and Chatelain, E. (2009) Drug discovery for neglected diseases: view of a public-private partnership, in Antiparasitic and Antibacterial Drug Discovery: From Molecular Targets to Drug Candidates (ed. P. Selzer), Wiley-VCH, Weinheim, Germany, pp. 33-43.
3. Moran, M.A. (2005) Breakthrough in R&D for neglected diseases: new ways to get the drugs we need. PLoSMed., 2, e309.
4. Croft, L.C. (2005) Public-private partnership: from there to here. Trans. R. Soc. Trop. Med. Hyg., 99 (Suppl. 1), S9-S14.
5. Caffrey, C.R. and Steverding, D. (2008) Recent initiatives and strategies to developing new drugs for tropical parasitic diseases. Curr. Opin. Drug Discov., 3, 173-186.
6. Selzer, P.M. (2009) Preface, in Antiparasitic and Antibacterial Drug Discovery: From Molecular Targets to Drug Candidates (ed. P. Selzer), Wiley-VCH, Weinheim, Germany.
7. Chassaing, C. and Sekljic, H. (2009) Approaches towards anti-parasitic drug candidates for veterinary use, in Antiparasitic and Antibacterial Drug Discovery: From Molecular Targets to Drug Candidates (ed. P. Selzer), Wiley-VCH, Weinheim, Germany, pp. 117-133.
8. Geary, T.G.,Woods, D.J., Williams, T. and Nwaka, S. (2009) Target identification and mechanism-based screening for anthelmintics: application of veterinary anti-parasitic research programs to search for new anti-parasitic drugs for human indications, in Anti-parasitic and Antibacterial Drug Discovery: From MolecularTargets to DrugCandidates (ed. P. Selzer), Wiley-VCH, Weinheim, Germany, pp. 3-15.
9. Mehlhorn, H. (2008) Encyclopedia of Parasitology, Springer Verlag, Heidelberg, Germany.
10. Caffrey, C.R., Rohwer, A., Oellien, F., Marhöfer, R.J., Braschi, S. et al. (2009) Acomparative chemogenomics strategy to predict potential drug targets in the metazoan pathogen, Schistosoma mansoni. PLoS One, 4, e4413.
11. Krasky, A., Rohwer, A., Marhöfer, R. and Selzer, P.M. (2009) Bioinformatics and chemoinformatics: key technologies in the drug discovery process, in Anti-parasitic and Antibacterial Drug Discovery: From Molecular Targets to Drug Candidates (ed. P. Selzer), Wiley-VCH, Weinheim, Germany, pp. 45-57.
12. Woods, D.J. and Williams, T.M. (2007) The challenges of developing novel antiparasitic drugs. Invert. Neurosci., 7, 245-250.
13. Noedl, H., Wongsrichanalai, C. and Wernsdorfer, W.H. (2003) Malaria drugsensitivity testing: new assays, new perspectives. Trends Parasitol., 19, 175-181.
14. Coles, G.C. (1990) Recent advances in laboratory models for evaluation of helminth chemotherapy. Br. Vet. J., 146, 113-119.
15. Kröber, T. andGuerin, P.M. (2007) In vitro feeding assays for hard ticks. Trends Parasitol., 23, 445-449.
16. Abdulla, M.H., Ruelas, D.S., Wolff, B., Snedecor, J., Lim, K.C., Xu, F. et al. (2009) Drug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by medium-throughput phenotypic screening. PLoS Negl. Trop. Dis., 3, e478.
17. Gassel, M., Cramer, J., Kern, C., Noack, S. and Streber, W. (2009) Lessons learned from target-based lead discovery, in Anti-parasitic and Antibacterial Drug Discovery: From Molecular Targets to Drug Candidates (ed. P. Selzer), Wiley-VCH, Weinheim, Germany, pp. 99-115.
18. Selzer, P.M., Brutsche, S., Wiesner, P., Schmid, P. and Mullner, H. (2000) Target-based drug discovery for the development of novel antiinfectives. Int. J. Med. Microbiol., 290, 191-201.
19. Selzer, P.M., Marhöfer, J.R. and Rohwer, A. (2008) Applied Bioinformatics, Springer Verlag, Heidelberg, Germany.
20. Kandpal, R., Saviola, B. and Felton, J. (2009) The era of 'omics unlimited'. Biotechniques, 46, 351-352, 354-355.
21. Cho, C.R., Labow, M., Reinhardt, M., van Oostrum, J. and Peitsch, M.C. (2006) The application of systems biology to drug discovery. Curr. Opin. Chem. Biol., 10, 294-302.
22. Frearson, J.A., Wyatt, P.G., Gilbert, I.H. and Fairlamb, A.H. (2007) Target assessment for anti-parasitic drug discovery. Trends Parasitol., 23, 589-595.
23. Köhler P. and Marhöfer, R. (2009) Selective drug targets in parasites, in Anti-parasitic and Antibacterial Drug Discovery: From Molecular Targets to Drug Candidates (ed. P. Selzer), Wiley-VCH, Weinheim, Germany, pp. 75-98.
24. Engel, J.C., Doyle, P.S., Hsieh, I. and McKerrow, J.H. (1998) Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection. J. Exp. Med., 188, 725-34.
25. Selzer, P.M., Pingel, S., Hsieh, I., Ugele, B., Chan, V.J. et al. (1999) Cysteine protease inhibitors as chemotherapy: lessons from a parasite target. Proc. Natl Acad. Sci. USA, 96, 11015-11022.
26. Wolf, C. and Gunkel, N. (2009) Target identification and validation in antiparasitic drug discovery, in Anti-parasitic and Antibacterial Drug Discovery: From Molecular Targets to Drug Candidates (ed. P. Selzer), Wiley-VCH, Weinheim, Germany, pp. 59-73.
27. Aurrecoechea, C., Brestelli, J., Brunk, B.P., Fischer, S., Gajria, B. et al. (2010) EuPathDB: a portal to eukaryotic pathogen databases. Nucleic Acids Res., 38 (Database issue), D415-D419.
28. Hertz-Fowler, C., Peacock, C.S.,Wood, V., Aslett, M., Kerhornou, A. et al. (2004) GeneDB: a resource for prokaryotic and eukaryotic organisms. Nucleic Acids Res., 32 (Database issue), D339-D343.
29. Agüero, F., Al-Lazikani, B., Aslett, M., Berriman, M., Buckner, F.S. et al. (2008) Genomic-scale prioritization of drug targets: the TDR Targets database. Nat. Rev. Drug Discov., 7, 900-907.
30. Chen, X., Jorgenson, E. and Cheung, S.T. (2009) New tools for functional genomic analysis. Drug Discov. Today, 14, 754-760.
31. Ansorge, W.J. (2009) Next-generation DNA sequencing techniques. Nat. Biotechnol., 25, 195-203.
32. Gupta, P.K. (2008) Single-molecule DNA sequencing technologies for future genomics research. Trends Biotechnol., 26, 602-611.
33. Winzeler, E.A. (2009) Advances in parasite genomics: from sequences to regulatory networks. PLoS Pathog., 5, e1000649.
34. Liolios, K., Mavromatis, K., Tavernarakis, N. and Kyrpides, N.C. (2008) The Genomes OnLine Database (GOLD) in 2007: status of genomic and metagenomic projects and their associated metadata. Nucleic Acids Res., 36 (Database issue), D475-D479.
35. Beckstette, M., Mailänder, J., Marhöfer, J.R., Sczyrba, A., Ohlebusch, E. et al. (2004) Genlight: an interactive system for high-throughput sequence analysis and comparative genomics. J. Integ. Bioinform., 8, 1.
36. Gerber, S., Krasky, A., Rohwer, A., Lindauer, S., Closs, E. et al. (2006) Identification and characterisation of the dopamine receptor II from the cat flea Ctenocephalides felis (CfDopRII). Insect Biochem. Mol. Biol., 36, 749-758.
37. Krasky, A., Rohwer, A., Schroeder, J. and Selzer, P.M. (2007) A combined bioinformatics and chemoinformatics approach for the development of new anti-parasitic drugs. Genomics, 89, 36-43.
38. Klotz, C., Marhöfer, R.J., Selzer, P.M., Lucius, R. and Pogonka, T. (2005) Eimeria tenella: identification of secretory and surface proteins from expressed sequence tags. Exp. Parasitol., 111, 14-23.
39. Blake, R.A. (2006) Target validation in drug discovery. Methods Mol. Biol., 356, 367-378.
40. Hillisch, A. and Hilgenfeld, R. (2003) The role of protein 3D-structures in the drug discovery process, in ModernMethods of Drug Discovery (eds A. Hillisch and R. Hilgenfeld), Birkhäuser, Basel, Switzerland, pp. 157-181.
41. Torrie, L.S., Wyllie, S., Spinks, D., Oza, S.L., Thompson, S. et al. (2009) Chemical validation of trypanothione synthetase: a potential drug target for human trypanosomiasis. J. Biol. Chem., 284, 36137-36145.
42. Sugiyama, Y. (2005) Druggability: selecting optimized drug candidates. Drug Discov. Today, 10, 1577-1579.
43. Betz, U.A. (2005) How many genomics targets can a portfolio afford' Drug Discov. Today, 10, 1057-1063.
44. Goodnow, R.A. Jr and Gillespie, P. (2007) Hit and lead identification: efficient practices for drug discovery. Prog. Med. Chem., 45, 1-61.
45. Ernst, A. and Obrecht, D. (2008) Case studies of parallel synthesis in hit identification, hit exploration, hit-to-lead and lead-optimization programs, in High- Throughput Lead Optimization in Drug Discovery (ed. T. Kshirsagar), CRC Press, Boca Raton, USA, pp. 99-116.
46. Mayr, L.M. and Bojanic, D. (2009) Novel trends in high-throughput screening. Curr. Opin. Pharmacol., 9, 580-588.
47. Pereira, D.A. and Williams, J.A. (2007) Origin and evolution of high throughput screening. Br. J. Pharmacol., 152, 53-61.
48. Kenny, B.A., Bushfield, M., Parry-Smith, D.J., Fogarty, S. and Treherne, J.M. (1998) The application of high-throughput screening to novel lead discovery. Prog. Drug Res., 51, 245-69.
49. Oellien, F., Engels, K., Cramer, J., Marhöfer, J.R., Kern, C. and Selzer, P.M. (2009) Searching new anti-parasitics in virtual space, in Anti-parasitic and Antibacterial Drug Discovery: From Molecular Targets to Drug Candidates (ed. P. Selzer), Wiley-VCH, Weinheim, Germany, pp. 323-338.
50. McInnes, C. (2007) Virtual screening strategies in drug discovery. Curr. Opin. Chem. Biol., 11, 494-502.
51. Köppen, H. (2009) Virtual screening - what does it give us' Curr. Opin. Drug Discov. Devel., 12, 397-407.
52. Keseru, G.M. and Makara, G.M. (2006) Hit discovery and hit-to-lead approaches. Drug Discov. Today, 11, 741-748.
53. Nogueira, R.C., Oliveira-Costa, J.F., de Sá, M.S., dos Santos, R.R. and Soares, M.B. (2009) Early toxicity screening and selection of lead compounds for parasitic diseases. Curr. Drug Targets, 10, 291-298.
54. Cockbain, J. (2007) Intellectual property rights and patents, in Comprehensive Medicinal Chemistry II, vol. 1 (eds J.B. Taylor and D.J. Triggle), Elsevier, Amsterdam, The Netherlands, pp. 779-815.
55. Lindsley, C.W., Weaver, D., Bridges, T.M. and Kennedy, J.P. (2009) Lead optimization in drug discovery, Wiley Encyclopedia of Chemical Biology, vol. 2, Wiley-VCH, Weinheim, pp. 511-519.
56. Colombo, M. and Peretto, I. (2008) Chemistry strategies in early drug discovery: an overview of recent trends. Drug Discov. Today, 13, 677-684.
57. Wess, G. (2002) How to escape the bottleneck of medicinal chemistry. Drug Discov. Today, 7, 533-535.
58. Di, L. and Kerns, E.H. (2003) Profiling drug-like properties in discovery research. Curr. Opin. Chem. Biol., 7, 402-408.
59. Meyer, T., Schröder, J., Uphoff, M., Noack, S., Heckeroth, A. et al. (2009) Chemical optimization of anthelmintic compounds - a case study, in Anti-parasitic and Antibacterial Drug Discovery: From Molecular Targets to Drug Candidates (ed. P. Selzer), Wiley-VCH, Weinheim, Germany, pp. 357-371.
60. Fotouhi N., Gillespie, P., Goodnow, R.A., So, S.S., Han, Y. and Babiss, L.E. (2006) Application and utilization of chemoinformatics tools in lead generation and optimization. Comb. Chem.High-Throughput Screen., 9, 95-102.
61. Andricopulo, A.D., Salud, L.B. and Abraham, D.J. (2009) Structure-based drug design strategies in medicinal chemistry. Curr. Top. Med. Chem., 9, 771-790.
62. Guido, R.V. and Oliva, G. (2009) Structure-based drug discovery for tropical diseases. Curr. Top.Med. Chem., 9, 824-843.
63. Schoonen, W.G., Westerink, W.M. and Horbach, G.J. (2009) High-throughput screening for analysis of in vitro toxicity. EXS (Basel), 99, 401-452.
64. Wang, J. and Skolnik, S. (2009) Recent advances in physicochemical and ADMET profiling in drug discovery. Chemistry & Biodiversity, 6, 1887-1899.
65. Caldwell, G.W., Yan, Z., Tang, W., Dasgupta, M. and Hasting, B. (2009) ADME optimization and toxicity assessment in early- and late-phase drug discovery. Curr. Top. Med. Chem., 9, 965-980.
66. Wykes, M.N. and Good, M.F. (2009) What have we learnt from mouse models for the study of malaria' Eur. J. Immunol., 39, 2004-2007.
67. Erhardt, P.W. and Proudfoot, J.R. (2007) Drug discovery: historical perspective, current status and outlook, in Comprehensive Medicinal Chemistry II, vol. 1 (eds J.B. Taylor and D.J. Triggle), Elsevier, Amsterdam, The Netherlands, pp. 29-96.
68. Padden, J., Skoner, D. and Hochhaus, G. (2008) Pharmacokinetics and pharmacodynamics of inhaled glucocorticoids. J. Asthma, 45, 13-24.
69. McKerrow, J.H., Rosenthal, P.J., Swenerton, R. and Doyle, P. (2008) Development of protease inhibitors for protozoan infections. Curr. Opin. Infect. Dis., 21, 668-672.
70. Rosenthal, P.J. (2004) Cysteine proteases of malaria parasites. Int. J. Parasitol., 34, 1489-1499.
71. Doyle P.S. Zhou, Y.M., Engel, J.C. and McKerrow, J.H. (2007) A cysteine protease inhibitor cures Chagas' disease in an immunodeficient-mouse model of infection. Antimicrob. Agents Chemother., 51, 3932-3939.
72. Kerr, I.D., Lee, J.H., Farady, C.J., Marion, R., Rickert, M. et al. (2009) Vinyl sulfones as anti-parasitic agents and a structural basis for drug design. J. Biol. Chem., 284, 25697-25703.
73. Kaminsky, R., Ducray, P., Jung, M., Clover, R., Rufener, L. et al. (2008) A new class of anthelmintics effective against drug-resistant nematodes. Nature, 452, 176-180.
74. Wolstenholme, A.J., Fairweather, I., Prichard, R., von Samson- Himmelstjerna, G. and Sangster, N.C. (2004) Drug resistance in veterinary helminths. Trends Parasitol., 20, 469-476.
75. von Samson-Himmelstjerna, G., Prichard, R.K. and Wolstenholme, A.J. (2009) Anthelmintic resistance as a guide to the discovery of new drugs' in Anti-parasitic and Antibacterial Drug Discovery: From Molecular Targets to Drug Candidates (ed. P. Selzer), Wiley-VCH, Weinheim, Germany, pp. 17-32.
76. Prichard R.K. and Geary, T.G. (2008) Drug discovery: fresh hope to can the worms. Nature, 452, 157-158.
77. Ducray, P., Gauvry, N., Pautrat, F., Goebel, T., Fruechtel, J. et al. (2008) Discovery of amino-acetonitrile derivatives, a new class of synthetic anthelmintic compounds. Bioorg. Med. Chem. Lett., 18, 2935-2938.
78. Hosking, B.C., Kaminsky, R., Sager, H., Rolfe, F. and Seewald,W. (2010) Apooled analysis of the efficacy of monepantel, an amino-acetonitrile derivative against gastrointestinal nematodes of sheep. Parasitol. Res., 106, 529-532.
79. Rufener, L., Mäser, P., Roditi, I. and Kaminsky, R. (2009) Haemonchus contortus acetylcholine receptors of the DEG-3 subfamily and their role in sensitivity to monepantel. PLoS Pathol., 5, e1000380.